✦ LIBER ✦

High-dose chemotherapy in high-risk myelodysplastic syndrome : Covariate-adjusted comparison of five regimens

✍ Scribed by Miloslav Beran; Yu Shen; Hagop Kantarjian; Susan O'Brien; Charles A. Koller; Francis J. Giles; Jorge Cortes; Deborah A. Thomas; Stefan Faderl; Simona Despa; Elihu H. Estey

Book ID: 101329680
Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 208 KB
Volume: 92
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(20011015)92:8<1999::aid-cncr1538>3.0.co;2-b

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Risk of secondary myeloid leukemia and m

Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies

✍ C. Kollmannsberger; J. T. Hartmann; L. Kanz; C. Bokemeyer 📂 Article 📅 1998 🏛 Springer-Verlag 🌐 English ⚖ 296 KB

A combination chemotherapy with low dose

A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage: A pilot study

✍ Shin-ichiro Kuriya; Kazunori Murai; Yasuro Miyairi; Taiju Utsugisawa; Yasushi Na 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 442 KB 👁 2 views

## BACKGROUND. Even now, no definitely effective therapy is inducted to high risk myelodysplastic syndromes (MDS) and their leukemic stage (MDS-AML) except bone marrow transplantation. ## METHODS. Ten patients with high risk MDS and 6 with MDS-AML were treated with daily low doses of cytarabine

Results of a randomized double-blind pla

Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes

✍ Walter Verbeek; Bernhard Wörmann; Peter Koch; Carl Aul; Hans-Fokke Hinrichs; Leo 📂 Article 📅 1999 🏛 Springer-Verlag 🌐 English ⚖ 99 KB

High-dose darbepoetin alpha in the treat

High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study

✍ L. Mannone; C. Gardin; M. C. Quarre; J. F. Bernard; D. Vassilieff; L. Ades; S. P 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

Prognostic relevance of achieving cytoge

Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy

✍ Sebastian Balleisen; Andrea Kuendgen; Barbara Hildebrandt; Rainer Haas; Ulrich G 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 249 KB

Cytogenetic findings at diagnosis have influence on prognosis in patients with acute myelogenous leukaemia (AML) or MDS who undergo induction chemotherapy. Assessment of remission and treatment decisions are based on cytological findings. We analyzed the prognostic impact of cytogenetic remission st

Intravenous itraconazole for prophylaxis

Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy

✍ Gloria N. Mattiuzzi; Hagop Kantarjian; Susan O'Brien; Dimitrios P. Kontoyiannis; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

## Abstract ## BACKGROUND Systemic fungal infections remain the leading cause of mortality in patients with newly diagnosed acute myelogenous leukemia (AML) and high‐risk myelodysplastic syndrome (MDS). The objective of the current study was to determine whether intravenous itraconazole (I.V. ITRA